Palma, Spain and San Diego, USA, August 20, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announces the appointment of Adam Levy as Chief Financial Officer.
Adam most recently worked at Brickell Biotech (BBI) as Director of Business Development. Adam brings an immense background in finance with over 20 years of operational and transactional experience in biotech and investment banking.
“It is a pleasure to welcome Adam to the Sanifit team in his new role as Chief Financial Officer, an appointment that greatly strengthens our management team. Adam joins us at an exciting time, and his impressive experience in strategy, corporate development and financing in the life sciences sector will be invaluable as we progress our SNF472 drug through Phase 3 clinical trials.” said Joan Perelló, CEO of Sanifit.
Adam has extensive financial experience in the healthcare sector. At Brickell Biotech, he has led the transition of the organization’s financial operations following its IPO on Nasdaq. From 2016 to 2019, he was Director of Business Development for miRagen therapeutics, where he was responsible for a variety of functions including financial strategy, investor relations, business development, legal, intellectual property, project management, and human resources. Adam successfully guided miRagen through several capital raises and its listing on Nasdaq.
Between 2000 and 2016, Mr. Levy held various investment banking positions at Merrill Lynch, Pierce, Fenner & Smith, Jefferies Group and Wedbush Securities. During that period, he completed over $30 billion in financing and M&A transactions for his clients.
Adam received his B.S. in Business Administration and Marketing, Magna Cum Laude, from the Dyson School of Applied Economics and Management, Cornell University.
– – –
More about Sanifit: www.sanifit.com